Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Frequently asked questions
What sector does Evommune, Inc. (EVMN) operate in?
Evommune, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Evommune, Inc. (EVMN) current stock price?
As of the latest data, Evommune, Inc. stock price is $14.65, with a previous close of $14.07. Evommune, Inc. gained $0.58 in the last trading session, representing a 4.12% increase.
What is Evommune, Inc. (EVMN) current market capitalization?
Evommune, Inc. market cap is approximately 531.68 million.
What is Evommune, Inc. (EVMN) Earnings Per Share (EPS)?
The trailing EPS is -$11.82, and the forward EPS is -$3.27.
Does Evommune, Inc. (EVMN) pay dividends?
No. Evommune, Inc. does not pay a dividend.
What is Evommune, Inc. (EVMN) beta (volatility) score?
Evommune, Inc. has a beta of 0.159, indicating lower volatility than the overall market.